Table 2.
Response patterns according to subgroups.
| n (% of all patients) | ORR n (%) | |
|---|---|---|
| Age >65 <65 |
23 (55%) 19 (45%) |
8 (35%) 4 (21%) |
| Melanoma subtype n (%) Cutaneous Acral Mucosal Uveal Unknown |
26 (62%) 6 (14%) 4 (10%) 5 (12%) 1 (2%) |
6 (23%) 4 (67%) 1 (25%) 1 (20%) 0 (0%) |
| BRAF V600 Mutation n (%) V600E/K Mutated Non V600 Mutated Wild type |
13 (31%) 1 (2%) 28 (67%) |
1 (8%) 1 (100%) 10 (36%) |
| ECOG PS n (%) 0 1 2 3 |
21 (50%) 12 (29%) 8 (19%) 1 (2%) |
7 (33%) 3 (25%) 2 (25%) 0 (0%) |
| Serum LDH n (%) Normal range Elevated <X2 UNL Elevated >X2 UNL Unknown |
14 (33%) 19 (45%) 8 (19%) 1 (2%) |
5 (36%) 5 (26%) 2 (25%) 0 (0%) |
| Metastatic at presentation n (%) Yes No |
7 (17%) 35 (83%) |
2 (29%) 10 (29%) |
| Active CNS metastases n (%) Yes No |
13 (31%) 29 (69%) |
4 (31%) 8 (28%) |
| Liver metastases n (%) Yes No |
17 (40%) 25 (60%) |
4 (23%) 8 (32%) |
| Bone metastases n (%) Yes No |
9 (21%) 33 (79%) |
1 (11%) 11 (33%) |
| Lenvatinib + Anti PD-1 line n (%) 2nd 3rd 4th 5th |
15 (35%) 13 (31%) 7 (17%) 7 (17%) |
3 (20%) 4 (31%) 3 (43%) 2 (29%) |
| Anti PD-1 agent used n (%) Pembrolizumab Nivolumab |
26 (62%) 16 (38%) |
8 (31%) 4 (25%) |
| Previous line n (%) Ipilimumab-Nivolumab Single agent Anti PD-1 |
37 (88%) 5 (12%) |
9 (24%) 3 (60%) |
| Type of immunotherapy resistance n (%) Primary Acquired |
22 (52%) 20 (48%) |
8 (36%) 4 (20%) |
| Grade 3-4 toxicity n (%) Yes No |
13 (31%) 29 (69%) |
6 (46%) 6 (21%) |
PS, performance status; LDH, lactate dehydrogenase; UNL, upper normal limit; CNS, central nervous system.